Cargando…
Control Crohn Safe with episodic adalimumab monotherapy as first-line treatment study (CoCroS): study protocol for a randomised controlled trial
INTRODUCTION: Crohn’s disease (CD) is a chronic inflammatory bowel disease with a heterogeneous clinical presentation, relapse rate and treatment response. At present, no markers are available to adequately predict disease course at diagnosis. To prevent overtreatment of patients with a relative mil...
Autores principales: | Janssen, Laura, Romberg-Camps, Mariëlle, van Bodegraven, Ad, Haans, Jeoffrey, Aquarius, Michèl, Boekema, Paul, Munnecom, Tamara, Brandts, Lloyd, Joore, Manuela, Masclee, Adrian, Jonkers, D, Pierik, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098960/ https://www.ncbi.nlm.nih.gov/pubmed/33947729 http://dx.doi.org/10.1136/bmjopen-2020-042885 |
Ejemplares similares
-
Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn’s disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course
por: Harris, Rachel E, et al.
Publicado: (2020) -
NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case–control study
por: Masclee, Gwen M C, et al.
Publicado: (2015) -
Lengthening adalimumab dosing interval in quiescent Crohn’s disease patients: protocol for the pragmatic randomised non-inferiority LADI study
por: Smits, L J T, et al.
Publicado: (2020) -
Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease
por: Spekhorst, Lieke M, et al.
Publicado: (2017) -
The reproducibility of skeletal muscle signal intensity on routine magnetic resonance imaging in Crohn's disease
por: Spooren, Corinne E.G.M., et al.
Publicado: (2020)